NCT04768036 is a NA clinical trial of IMPROVE DD VTE Tool in Venous Thromboembolism, sponsored by Northwell Health.

Who is sponsoring NCT04768036?

NCT04768036 is sponsored by Northwell Health.

What drugs are being tested in NCT04768036?

Interventions in NCT04768036: IMPROVE DD VTE Tool.

What condition does NCT04768036 study?

NCT04768036 studies Venous Thromboembolism, Arterial Thromboembolism.

Is NCT04768036 still recruiting?

NCT04768036 is currently completed. Last updated 2 August 2022.

Last reviewed 2022-08-02 · How we verify

NCT04768036

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Universal Electronic Health Record-based IMPROVE DD VTE Risk Assessment Model for the Prevention of Thromboembolism in Hospitalized Medically Ill Patients

Completed NA Last updated 2 August 2022

What this trial tests

NA trial testing IMPROVE DD VTE Tool in Venous Thromboembolism in 10,699 participants. Completed in 21 January 2022.

Timeline

21 December 2020

Primary endpoint
21 January 2022

21 January 2022

Quick facts

Lead sponsor	Northwell Health
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	10,699
Start date	21 December 2020
Primary completion	21 January 2022
Estimated completion	21 January 2022
Sites	5 locations across United States

Drugs / interventions tested

IMPROVE DD VTE Tool

Conditions studied

Venous Thromboembolism — all drugs for Venous Thromboembolism →
Arterial Thromboembolism — all drugs for Arterial Thromboembolism →

Sponsor

Northwell Health — full company profile →

Who can join

60 and older, any sex, with Venous Thromboembolism or Arterial Thromboembolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be a multicenter clustered randomized trial of patients in hospitals in which a universal "SMART on FHIR" platform-based EHR-embedded IMPROVE DD VTE clinical prediction rules (CPRs) with electronic order entry has been incorporated into required admission and discharge EHR workflow versus hospitals following UMC for VTE risk assessment of medically ill patients. The patient population will consist of hospitalized, medically ill (non-surgical, non-obstetrical) individuals aged \> 60 years.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The Use of Risk Scores for Thromboprophylaxis in Medically Ill Patients-Rationale and Design of the RICO trial.
Dentali F, Campanini M, Bonaventura A, Fontanella L, et al · · 2024 · cited 4× · PMID 38222040 · DOI 10.1055/a-2209-4708
To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients.
Spyropoulos AC. · · 2022 · cited 4× · PMID 36485109 · DOI 10.1182/hematology.2022000403
Universal EHRs Clinical Decision Support for Thromboprophylaxis in Medical Inpatients : A Cluster Randomized Trial
Spyropoulos A, Goldin M, Koulas I, Solomon J, et al · · 2023

Verify or expand the search:

Other recruiting trials for Venous Thromboembolism

Currently open trials in the same condition.

NCT07399977 — Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism · NA · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT07140523 — A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA · Phase 2 · recruiting
NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
NCT06440694 — Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) · Phase 3 · recruiting

Other Northwell Health trials

Trials by the same sponsor.

NCT07253662 — Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Aden · Phase 1 · recruiting
NCT07191041 — Emotional Urinary Tract Infection · not yet recruiting
NCT07254091 — Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer · EARLY_PHASE1 · recruiting
NCT07344961 — Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB) · recruiting
NCT07193862 — Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Meta · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04768036 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Northwell Health
Last refreshed: 2 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04768036.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing